ArticleCancer medicine2021
Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Systematic review of PET imaging features and clinical applications in pulmonary NUT carcinoma.Frontiers in radiology · 2026Pooled it
- Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis.Frontiers in oncology · 2023Pooled it
- Article
- ITIH2 in colorectal cancer metastasis: Weighted Gene Co-expression Network Analysis-guided functional validation.PloS one · 2026Article
- Rapid Progression of Primary Pulmonary NUT Midline Carcinoma: A Case Report and Literature Review.Respirology case reports · 2025Article
- Pulmonary Nuclear protein in Testis (NUT) carcinoma: clinical, molecular characteristics, and treatment strategies.BMC cancer · 2025Article
- NUT carcinoma of the submandibular gland: A case report.Cancer reports (Hoboken, N.J.) · 2023Article
- Prolonged Survival of NUT Midline Carcinoma and Current Approaches to Treatment.The oncologist · 2023Article
- Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case.Journal of cancer research and clinical oncology · 2023Article
- Targeted therapy for rare lung cancers: Status, challenges, and prospects.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Clinicopathological molecular characterizations of sinonasal NUT carcinoma: a report of two cases and a literature review.Frontiers in oncology · 2023Article
- Multimodality imaging and treatment of paranasal sinuses nuclear protein in testis carcinoma: A case report.World journal of clinical cases · 2022Article
- Clinical imaging of primary pulmonary nucleoprotein of the testis carcinoma.Frontiers in medicine · 2022Article
- Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionPulmonary nuclear protein of the testis (NUT) midline carcinoma (NMC) is a aggressive cancer with t (15, 19) translocation. Here we present the clinicopathological characteristics and molecular genetics alterations of primary pulmonary NMC.
methodsFluorescence in situ hybridization (FISH) assay was performed to evaluate NUT translocation. Next generation sequencing (NGS) was performed to investigate genomic landscape. A panel of 289 lung cancer tissues with undifferentiation was retrospectively screened for NUT expression by immunohistochemical (IHC) assay.
resultsOverall, 2136 lung cancer samples were reviewed. We consecutively identified 12 cases of primary pulmonary NMC. Computed tomography revealed centrally located bulky lung mass with ipsilateral mediastinal lymph node and pleural involvements. Tumor cells presented diffuse poor differentiation and focal squamous differentiation with positive NUT expression. NUT rearrangement was confirmed by FISH assay. Ten NMC samples were investigated by NGS. The most common alterations identified were P53, PIK3CA, AUTS2, ITIH2, and CDKL5 genes. Pulmonary NMC exhibited increased activity of PI3K/AKT pathway. In the screening study, BRD4-NUT rearrangement was identified in two cases.
conclusionNUT rearrangement remains the gold standard in the diagnosis of pulmonary NMC. PI3K inhibition is a potential targeted therapy for pulmonary NMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.